-transparent.png){kind=logo}
Cetiedil was found to inhibit platelet aggregation and thromboxane synthesis induced by thrombin and arachidonic acid. When platelets were activated by thrombin, half maximal inhibition (ED50 effective dose of cetiedil necessary for 50% inhibition) for platelet aggregation was 100 microM while that for thromboxane B2 (TXB2) production was 50 microM. When arachidonic acid was used, the ED50 for platelet aggregation was 100 microM while that for TXB2 production was 150 microM. The presence of calcium ions did not affect on the inhibitory effects of cetiedil. The cAMP level in platelets did not increase after incubation with cetiedil. Cetiedil appears to inhibit the activation of platelets related to thromboxane synthesis.
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
November 1983,
British medical journal (Clinical research ed.),
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
May 1987,
Thrombosis research,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
June 1979,
Prostaglandins and medicine,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
January 1985,
Nature,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
July 1984,
Thrombosis research,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
January 1982,
Cardiologia (Rome, Italy),
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
April 1979,
Lancet (London, England),
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
March 1991,
Thrombosis and haemostasis,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
January 1984,
Investigative radiology,
A Yamaguchi, and
T Asakura, and
K Tanoue, and
H Yamazaki
January 1980,
Advances in prostaglandin and thromboxane research,
